<DOC>
	<DOCNO>NCT00001547</DOCNO>
	<brief_summary>Use drug interferon-alpha ( IFN-A ) , associate frequent well characterized side effect like neurotoxicity . Neurotoxicity cause symptom depression , agitation , anxiety , and/or confusion . The NIDDK conduct research study call , `` Combination Alpha Interferon Long Term Ribavirin Therapy Patients Chronic Hepatitis C '' ( 98-DK-0003 ) . Patients participate receive interferon-alpha addition antiviral medication call ribavirin . Researchers NIMH intend study patient learn different medication influence mood , thought behavior . The primary purpose study determine treatment IFN-A combination ribavirin alters human brain biochemistry measure proton magnetic resonance spectroscopy ( MRS ) . MRS use strong magnetic field order measure biochemical product metabolism find brain . Researchers intend perform MRS scan , , patient receive medication Researchers believe combination IFN-A/Ribavirin directly affect specific area brain result , patient develop specific mood cognitive symptom . Patients often must stop take medication side effect . This study contribute directly treatment patient 's Hepatitis C condition . However , information gather study help researcher well understand neuropsychiatric affect associate interferon alpha ribavirin therapy .</brief_summary>
	<brief_title>Neuropsychiatric Effects Interferon-Alpha Ribavirin</brief_title>
	<detailed_description>The systemic administration interferon-alpha ( IFN-A ) associate frequent well characterize neuropsychiatric toxicity . The primary purpose study determine treatment IFN-A combination ribavirin alters human brain biochemistry measure proton magnetic resonance spectroscopy . The study population drawn subject simultaneously enrol NIDDK protocol ( 98-DK-0003 ) employ IFN-A ribavirin treatment hepatitis C virus ( HCV ) infection . Subjects evaluate prior IFN-A/ribavirin treatment follow prospectively specific aim identify emergence central nervous system ( CNS ) effect . The principal outcome measure follow : determination specific brain metabolite measure proton magnetic resonance spectroscopy ( 1H-MRS ) , brief , non-invasive , minimal risk procedure ; rating mood , cognitive , behavioral symptom . The hypothesis test study follow : 1 . Treatment IFN-A/ribavirin decrease measure neuronal integrity ( NAA/CRE ratio ) brain region specific fashion . 2 . The degree change NAA/CRE certain brain region ( e.g . prefrontal cortex ) correspond development mood cognitive symptom . The question ask study relevant clinical management HCV patient , since adverse neuropsychiatric effect IFN-A ribavirin frequently complicate protocol participation occasionally result subject take protocol . There anticipated number patient day per year require study , participant simultaneously enrol NIDDK protocol 98-DK-0003 .</detailed_description>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Subjects must least 18 year age . Subjects eligible study enrol NIDDK protocol 98DK0003 consequently increase risk development neuropsychiatric toxicity . Subjects must able provide inform consent . No individual critically ill markedly agitate confuse . No individual implant cardiac pacemaker autodefibrillators . No individual implant neural pacemaker . No individual CNS aneurysmal clip . No individual cochlear implant . No individual metallic foreign body eye CNS . No individual form implant wire metal device may concentrate radiofrequency field . No pregnant woman . No individual history moderate severe claustrophobia .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2002</verification_date>
	<keyword>Drug</keyword>
	<keyword>Imaging</keyword>
	<keyword>Brain</keyword>
	<keyword>Metabolism</keyword>
	<keyword>Organic Mental Syndrome</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
	<keyword>Spectroscopy</keyword>
	<keyword>Neuropsychiatric Disorders</keyword>
	<keyword>Drug Effects</keyword>
	<keyword>Interferon-alpha</keyword>
</DOC>